Project item | Indications | Research phase | Cooperation demands |
BDA202204 | “hard-to-treat” solid tumors (pancreatic, gastric, etc) | License-out or co-development | License-out or co-development |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TR2-R52H9 | Rabbit | Rabbit TROP-2 / TACSTD2 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
TR2-H82Ea | Human | Biotinylated Human TROP-2 / TACSTD2 (88-274) Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
MBS-K028 | Human | Human TROP-2-coupled Magnetic Beads | |||
TR2-C52H4 | Canine | Canine TROP-2 / TACSTD2 Protein, His Tag | ![]() |
![]() ![]() |
|
TR2-R52H3 | Cynomolgus / Rhesus macaque | Rhesus macaque / Cynomolgus TROP-2 / TACSTD2 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
TR2-M52H6 | Mouse | Mouse TROP-2 / TACSTD2 Protein, His Tag | ![]() |
![]() ![]() |
|
TR2-H5253 | Human | Human TROP-2 / TACSTD2 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
TR2-H82E5 | Human | Biotinylated Human TROP-2 / TACSTD2 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
TR2-H5223 | Human | Human TROP-2 / TACSTD2 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Sacituzumab govitecan | IMMU-132; TROP-2-SN-38; IMMU0132; GS-0132 | Approved | Immunomedics Inc | Trodelvy, 拓达维 | Mainland China | Triple Negative Breast Neoplasms | Everest Medicines (Suzhou) Inc | 2020-04-22 | Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Brain metastases; Metastatic breast cancer; Endometrial Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Solid tumours; Carcinoma, Transitional Cell; Glioblastoma; Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Liver Failure | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
PF-06664178 | PF06664178; PF-06664178 | Pfizer Inc | Details | ||
BL-M02D1 | Phase 1 Clinical | Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms | Details | |
BIO-106 | BIO-106 | Phase 2 Clinical | Hangzhou Baikai Biopharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
DAC-002 | JS-108; DAC-002 | Phase 1 Clinical | Hangzhou Dac Biotech Company Ltd | Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms | Details |
FDA018 Antibody Drug Conjugate | Phase 2 Clinical | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms | Details | |
KJ-103 | KJ-103 | Phase 1 Clinical | Kisoji Biotechnology Inc | Rejection of renal transplantation; Solid tumours | Details |
BAT-8008 | BAT8008; BAT-8008 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours; Neoplasms | Details |
重组人源化抗Trop2单抗-SN38偶联物 | ESG-401; STI-3258 | Phase 2 Clinical | Shanghai Escugen Biotechnology Co Ltd, Tot Biopharm Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms | Details |
SKB-264 | SKB-264 | Phase 3 Clinical | Sichuan Kelun Pharmaceutical Co Ltd | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Breast Neoplasms; Endometrial Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
SHR-A1921 | SHR-A1921; SHRA1921 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd | Solid tumours | Details |
Datopotamab deruxtecan | Dato-DXd; DS-1062a; DS-1062 | Phase 3 Clinical | Daiichi Sankyo Co Ltd | Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
This web search service is supported by Google Inc.